Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study

By Olivier Rixe   Jean-baptiste Meric   David Khayat   Claude Soubrane   Roger Mouawad  

Cytokines, Cellular & Molecular Therapy, Vol. 7, Iss. 4, 2002-12 ,pp. : 151-156

Informa Healthcare

Access to resources Recommend Favorite

Differential Responses to Chemoimmunotherapy in Patients with Metastatic Malignant Melanoma

By Mainwaring P.N.   Atkinson H.   Chang J.   Moore J.   Hancock B.W.   Guillou P.J.   Oskam R.   Gore M.E.  

European Journal of Cancer, Vol. 33, Iss. 9, 1997-08 ,pp. : 1388-1392

Elsevier

Access to resources Recommend Favorite

Clinical Significance of Serum S100 in Metastatic Malignant Melanoma

By Hua B.G.   Stoffel-Wagner B.   Bierwirth T.   Mezger J.   Klingmuller D.  

European Journal of Cancer, Vol. 31, Iss. 11, 1995-10 ,pp. : 1898-1902

Elsevier

Access to resources Recommend Favorite

Clinical significance of serum S100 in metastatic malignant melanoma

By Guo H.B.   Stoffel-Wagner B.   Bierwirth T.   Mezger J.   Klingmuller D.  

European Journal of Cancer, Vol. 31, Iss. 6, 1995-06 ,pp. : 924-928

Elsevier

Access to resources Recommend Favorite

Malignant Melanoma Metastatic to the Ovary

By Piura B.   Kedar I.   Ariad S.   Meirovitz M.   Yanai-Inbar I.  

Gynecologic Oncology, Vol. 68, Iss. 2, 1998-02 ,pp. : 201-205

Elsevier

Access to resources Recommend Favorite